A recombinant HGP44 inhibited HIV-1 replication at a 50% effective concentration of approximately 2.5 micromolar, the researchers note, somewhat less potently than did P. gingivalis extracts.
The recombinant protein vaccine is the third type of COVID-19 vaccine that China has provided to other countries, following inactivated vaccines and adenovirus vector vaccines.
Soon after, others began using plasmid vectors and adding genes for antibiotic resistance, greatly increasing the reach of the recombinant techniques. [81]
The developers say the level of neutralizing antibody elicited by the vaccine is comparable to other COVID-19 recombinant protein vaccines and mRNA vaccines in the world.